Faraday Pharmaceuticals Patents – Insights & Stats (Updated 2023)

Faraday Pharmaceuticals has a total of 39 patents globally, out of which 7 have been granted. Of these 39 patents, more than 33% patents are active. The United States of America is where Faraday Pharmaceuticals has filed the maximum number of patents, followed by Australia and Europe. Parallely, United States of America seems to be the main focused R&D centre and also is the origin country of Faraday Pharmaceuticals.

Faraday Pharmaceuticals was founded in 2014. The Company is an early-stage biopharmaceutical firm focused on discovering innovative medicines to address ischemia-reperfusion injury. It has licensed patented liquid formulations of reduced nonmetal gaseous elements created by Dr. Mark Roth’s group at the Fred Hutchinson Cancer Research Center.

Do read about some of the most popular patents of Faraday Pharmaceuticals which have been covered by us in this article and also you can find Faraday Pharmaceuticals patents information, the worldwide patent filing activity and its patent filing trend over the years, and many other stats over Faraday Pharmaceuticals patent portfolio.

How many patents does Faraday Pharmaceuticals have?

Faraday Pharmaceuticals has a total of 39 patents globally. These patents belong to 17 unique patent families. Out of 39 patents, 13 patents are active.

How Many Patents did Faraday Pharmaceuticals File Every Year?

Faraday Pharmaceuticals Patent Filing Trend

Are you wondering why there is a drop in patent filing for the last two years? It is because a patent application can take up to 18 months to get published. Certainly, it doesn’t suggest a decrease in the patent filing.

Year of Patents Filing or GrantFaraday Pharmaceuticals Applications FiledFaraday Pharmaceuticals Patents Granted
20222
20211
20208
20196
20182
20111

How many Faraday Pharmaceuticals patents are Alive/Dead?

Worldwide Patents

Faraday Pharmaceuticals Patent Portfolio

How Many Patents did Faraday Pharmaceuticals File in Different Countries?

Faraday Pharmaceuticals Worldwide Patent Filing

Countries in which Faraday Pharmaceuticals Filed Patents

CountryPatent
United States Of America7
Australia5
Europe3
Israel2
Germany2
Mexico2
Canada2
India1
New Zealand1
Ireland1
Austria1
Hong Kong (S.A.R.)1

Where are Research Centers of Faraday Pharmaceuticals Patents Located?

R&D Centers of Faraday Pharmaceuticals

Best Faraday Pharmaceuticals Patent

US20060270741A1 is the most popular patent in the Faraday Pharmaceuticals portfolio. It has received 20 citations so far from companies like Signal Biosciences, Astellas Pharma and Lycera Corporation.

What Percentage of Faraday Pharmaceuticals US Patent Applications Were Granted?

Faraday Pharmaceuticals (Excluding its subsidiaries) has filed 2 patent applications at USPTO so far (Excluding Design and PCT applications). Out of these 0 have been granted leading to a grant rate of 0%.

Below are the key stats of Faraday Pharmaceuticals patent prosecution at the USPTO.

Which Law Firms Filed Most US Patents for Faraday Pharmaceuticals?

Law FirmTotal ApplicationsSuccess Rate
Cooley Llp20%

List of Faraday Pharmaceuticals Patents

Faraday Pharmaceuticals PatentsTitle
US20220387483A1Use Of Iodide Compounds For The Treatment And Prevention Of Chemotherapy-Associated Cachexia And Cardiotoxicity
US20210252047A1Use Of Halogen Compounds For The Treatment And Prevention Of Tissue Injury And Post-Intensive Care Syndrome
CA3160144A1Use Of Iodide Compounds For The Treatment And Prevention Of Chemotherapy-Associated Cachexia And Cardiotoxicity
CA3102792A1Use Of Halogen Compounds For The Treatment And Prevention Of Tissue Injury And Post-Intensive Care Syndrome
AU2020417997A1Use Of Iodide Compounds For The Treatment And Prevention Of Chemotherapy-Associated Cachexia And Cardiotoxicity
AU2019282820A1Use Of Halogen Compounds For The Treatment And Prevention Of Tissue Injury And Post-Intensive Care Syndrome
IL292688AUse Of Iodide Compounds For The Treatment And Prevention Of Chemotherapy-Associated Cachexia And Cardiotoxicity
IL279221AUse Of Halogen Compounds For The Treatment And Prevention Of Tissue Injury And Post-Intensive Care Syndrome
MX2022005347AUse Of Iodide Compounds For The Treatment And Prevention Of Cachexia And Cardiotoxicity Associated With Chemotherapy
IN202217030541AUse Of Iodide Compounds For The Treatment And Prevention Of Chemotherapy-Associated Cachexia And Cardiotoxicity
HK40050755AUse Of Halogen Compounds For The Treatment And Prevention Of Tissue Injury And Post-Intensive Care Syndrome
NZ788676AUse Of Iodide Compounds For The Treatment And Prevention Of Chemotherapy-Associated Cachexia And Cardiotoxicity
MX2020013306AUse Of Halogen Compounds For The Treatment And Prevention Of Tissue Injury And Post-Intensive Care Syndrome.
US8038995B2Human N-Type Calcium Channel Isoform And Uses Thereof
US7651175B2Parking Brake System
US20200096496A1Iodide Detection In Blood Plasma Samples
US20070265348A1Therapeutic Guanidines
US20060270741A1Pharmaceutically Active Compounds And Methods Of Use
DE69233479T2Substituted Guanidines And Derivatives Thereof As Modulators Of Neurotransmitter Release And New Method For Identifying Inhibitors Of Neurotransmitter Release
DE69233479D1Substituted Guanidines And Derivatives Thereof As Modulators Of Neurotransmitter Release And New Method For Identifying Inhibitors Of Neurotransmitter Release
EP0940139B1Substituted Guanidines And Derivatives Thereof As Modulators Of Neurotransmitter Release And Novel Methodology For Identifying Neurotransmitter Release Blockers
EP4054593A1Use Of Iodide Compounds For The Treatment And Prevention Of Chemotherapy-Associated Cachexia And Cardiotoxicity
EP3801565A4Use Of Halogen Compounds For The Treatment And Prevention Of Tissue Injury And Post-Intensive Care Syndrome
AT288262TSubstituierte Guanidine Und Derivate Hiervon Als Modulatoren Der Freisetzung Von Neurotransmittern Und Neue Methode Zur Identifizierung Von Inhibitoren Der Neurotransmitter-Freisetzung
IE20030530A1Guanidines And Derivatives
WO2021137932A1Use Of Iodide Compounds For The Treatment And Prevention Of Chemotherapy-Associated Cachexia And Cardiotoxicity
WO2019237065A1Use Of Halogen Compounds For The Treatment And Prevention Of Tissue Injury And Post-Intensive Care Syndrome
WO2018232179A1Iodide Detection In Blood Plasma Samples
WO2005097112A3Ion Channel Modulators
WO2005086892A3Ion Channel Modulators
WO2005086836A3Ion Channel Modulators
WO2005001060A3Novel Calcium Channel
WO2004072255A3Methods Of Treating Disease
WO2004071433A3Methods Of Treating Disease
WO2004072615A2Methods For Identifying Ion Channel Modulators
WO2003095620A3Oocyte Recording Chamber
AU2003203801B8Pharmaceutically Active Compounds And Methods Of Use
AU771437B2Methods For Treating Neurological Injuries And Disorders
AU2003228950A1Oocyte Recording Chamber

What are Faraday Pharmaceuticals key innovation segments?

What Technologies are Covered by Faraday Pharmaceuticals?

The chart below distributes patents filed by Faraday Pharmaceuticals in different countries on the basis of the technology protected in patents. It also represents the markets where Faraday Pharmaceuticals thinks it’s important to protect particular technology inventions.

R&D Focus: How has Faraday Pharmaceuticals search focus changed over the years?

EXCLUSIVE INSIGHTS COMING SOON!

Interested in knowing about the areas of innovation that are being protected by Faraday Pharmaceuticals?

Related Articles

Fiberstore Patents – Insights & Stats (Updated 2024)

Fiberstore has a total of 326 patents globally, out of which 285 have been granted. Of these 326 patents, more than 97% patents are active. China is where Fiberstore has filed the maximum number of patents, followed by United States of America and Europe (EPO). Parallelly, China seems to be

Read More »

Leave a Comment

Fill the form to get the details:

Fill the form to get the details:

Our comprehensive report provides an in-depth look into the patent portfolio. The report includes a breakdown of the patent portfolio across various technologies, listing the patent along with brief summaries of each patent's technology.